A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer
This trial is active, not recruiting.
|Conditions||rectal cancer, neoplasm metastasis|
|Treatments||capecitabine, pelvic radiation|
|Sponsor||AHS Cancer Control Alberta|
|Start date||January 2002|
|Trial size||66 participants|
|Trial identifier||NCT00122291, 16080, Capecitabine Phase 2|
The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Male or female participants at least 17 years old.
Inclusion Criteria: - Biopsy - proven rectal cancer - Transmural rectal wall invasion - Karnofsky performance status >70 - Normal bone marrow, liver and kidney function Exclusion Criteria: - Distant metastases - Prior pelvic radiation - Inflammatory bowel disease - Severe ischemic heart disease - Anticoagulant therapy - Pregnancy
|Official title||A Phase 2 Study of Preoperative Radiation Therapy and Capecitabine (an Oral Fluoropyrimidine Carbamate) in Locally Advanced Rectal Cancer|
|Principal investigator||Gwyn Bebb, MD|
|Description||The purpose of this trial is to study the efficacy of preoperative radiation therapy and capecitabine in locally advanced rectal cancer.|
Call for more information